
measured using CuKα radiation and a ^{13}C solid state NMR spectrum comprising peaks at chemical shifts of 176.8 and 168.4 ppm (± 0.2 ppm).

6. The crystalline sodium salt according to claim 2 in substantially pure form, wherein at least 80% of the substance is present in the form of the crystalline sodium salt.

7. A process for preparing a crystalline sodium salt of the compound of the following formula (1):



(1)

said process comprising the following steps:

(a) reacting Compound (1) with an aqueous NaOH solution in a suitable solvent to form a clear solution;

(b) adding methyl ethylketone to the mixture obtained in step (a) while heating the mixture to a temperature of about 50-60 °C;


(c) optionally, adding Compound (1) sodium salt methyl ethylketone solvate seeds to the mixture obtained in step (b) at about 50°C;

(d) adding additional methyl ethylketone to the mixture obtained in step (b) or (c) at about 50 °C; and

(e) cooling the mixture obtained in step (d) to about 25 °C, resulting in precipitation of Compound (1) sodium salt crystals.

8. A crystalline sodium salt prepared by the process according to claim 7.

9. A pharmaceutical composition comprising a crystalline sodium salt of the compound of the following formula (1):



(1)

and at least one pharmaceutically acceptable carrier or diluent.

10. A pharmaceutical composition according to claim 9, wherein the crystalline sodium salt has:

(a) an X-ray powder diffraction pattern comprising peaks at 7.5 and 20.4 degrees 2θ (± 0.2 degrees 2θ) when measured using CuKα radiation; or

(b) a ^{13}C solid state NMR spectrum comprising peaks at chemical shifts of 176.8 and 168.4 ppm (± 0.2 ppm); or

(c) both an X-ray powder diffraction pattern comprising peaks at 7.5 and 20.4 degrees 2θ (± 0.2 degrees 2θ) when measured using CuKα radiation and a ^{13}C solid state NMR spectrum comprising peaks at chemical shifts of 176.8 ppm and 168.4 ppm (± 0.2 ppm).

11. The pharmaceutical composition according to claim 10, wherein the crystalline sodium salt is in substantially pure form, wherein at least 80% of the substance is present in the form of the crystalline sodium salt.

12. A pharmaceutical composition according to claim 9 comprising:

(a) Compound (1) crystalline sodium salt;

(b) at least one surfactant;

(c) at least one basifier;

and optionally one or more pharmaceutically acceptable excipients.

17. A process for preparing an amorphous formulation comprising the following steps (1) to (4) or (5) to (8):

(1) mixing an active pharmaceutical ingredient, a polymer, a volatile solvent and, optionally, a soluble excipient to form a wet mass;

(2) feeding the wet mass into a temperature equilibrated extruder to form an extrudate;

(3) drying the extrudate;

(4) optionally screening the dried extrudates and mixing them with additional pharmaceutically acceptable excipients;

or:


(5) mixing an active pharmaceutical ingredient, a polymer and, optionally, a soluble excipient to form a mixture;

(6) feeding the mixture and a volatile solvent simultaneously into a temperature equilibrated extruder to form an extrudate;

(7) drying the extrudate;


(8) optionally screening the dried extrudates and mixing them with additional pharmaceutically acceptable excipients.

18. A compound of formula VII:




VII

19. A compound of formula I:




I

20. A compound of formula V or VI:




V




VI


21. A compound having the following structure:



22. A compound having the following structure:



23. A compound of formula III:



III

24. Use of a compound according to any one of claims 18 to 23 for preparing a compound of formula (1) as defined in claim 1.

25. Use of a compound according to any one of claims 18 to 23 for preparing the sodium salt according to any one of claims 1 to 6, 8, 13 to 14.